Celadon Pharmaceuticals Regulatory News (CEL)

27 Sep 2007 07:03

Celsis International PLC27 September 2007 STOCK EXCHANGE ANNOUNCEMENTFOR RELEASE: 7.00am - Thursday 27 September 2007 CELSIS INTERNATIONAL PLC("Celsis", "the Company" or "the Group") Pre Close trading update 27 September 2007: Celsis International plc, the life sciences products andlaboratory services company, today announces an update on trading prior to thecommencement of its close period. The Company has made significant progress in the first half of the year and ison track to announce strong revenue and solid operating profit growth for thesix months ended 30 September 2007. The Rapid Detection division is performing very well and has made a strongrecovery from last year's first half performance following a temporary slow downin instrument sales due to industry consolidations. Focus on the pharmaceuticalmarket continues as this division expands its presence in the rapidly growingmicrobial contamination market. Rapid testing reagent sales remain healthy andinstrument placements have improved across all segments of this business. The Analytical Services division is also performing well at both of its Missouriand New Jersey locations in the first half year, although it has seen asignificant chemistry contract in its New Jersey location wind down which willmoderate the improved breadth of growth during the period. The AnalyticalServices business remains strong overall and is benefiting from last year'sexceptional revenue increases, from the New Jersey Chemistry business, and isconsolidating these significant increases in growth. The In Vitro Technologies division has also seen a positive first half and is ontrack with expectations. Celsis' approach to grow this business is ongoing withupgrades to the IVT facility and a continued focus on higher margin products.The drug development services business, now part of the comprehensive serviceoffering from the Analytical Services division, is expanding well with furthercross-selling opportunities as well as via its own dedicated businessdevelopment team focused on new sales. Celsis will announce its interim results for the six months ended 30 September2007, on Wednesday 31 October 2007. There will be a presentation to analysts onthe day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 SouthamptonBuildings, London, WC2A 1PB. Jay LeCoque, Chief Executive Officer of Celsis, commented: "I am pleased to report a continued strengthening of performance from Celsis andthat we are in line to announce another overall strong set of results for thefirst half of this year. The company is well placed for future growth in bothrevenues and profits and we are confident that our strategy for each divisionwill continue to drive the growth of the Celsis Group." Enquiries:Celsis International plc Tel: 01223 598 428Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113 Ben AtwellDavid Yates Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life scienceproducts and laboratory services to the pharmaceutical, biopharmaceutical, andconsumer products industries through its three business areas; rapid detection,analytical and drug development services and ADME-Tox in vitro technologies.The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliversubstantial time and cost savings to its customers, in addition to ensuringproduct quality and safety for consumers. Using proprietary technology, theCelsis Rapid Detection division provides diagnostic systems for the rapiddetection of contamination. These systems provide significant economic value byreducing the time it takes to test and release raw materials, in process andfinished goods to market. Celsis Analytical Services division provides costeffective outsourced laboratory testing services to pharmaceutical andbiopharmaceutical companies. Its comprehensive service offerings include a fullspectrum of laboratory services from drug development and discovery toanalytical chemistry and biological sciences to stability storage and testing.Celsis In Vitro Technologies (Celsis IVT) supplies in vitro testing products tothe pharmaceutical and biotechnology industries. IVT's in vitro products screendrug compounds early in the discovery process, thereby reducing the time andcost of drug development. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange